Advice
following a full submission:
tocilizumab (RoActemra) is accepted for use within NHS Scotland.
Indication under review: treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Tocilizumab can be given as monotherapy (in case of intolerance to methotrexate or where treatment with methotrexate is inappropriate) or in combination with methotrexate.
Tocilizumab was superior to placebo in reducing disease activity and fever in patients with persistent active systemic juvenile idiopathic arthritis despite treatment with NSAIDs and corticosteroids.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of tocilizumab. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland.
Download detailed advice203KB (PDF)
Medicine details
- Medicine name:
- tocilizumab (RoActemra)
- SMC ID:
- 754/12
- Indication:
- For the treatment of systemic Juvenile Idiopathic Arthritis
- Pharmaceutical company
- Roche
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 February 2012
Additional notes
The marketing authorisation for this indication was extended to include children aged 1 year of age and older in November 2018 . This minor licence extension will not be assessed.